Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.

Zhou J, Limsakun T, Yin O, Warren V, Zamora C, Atiee G, Kochan J, Pav J, Kobayashi F, Vashi V, Dishy V.

J Clin Pharmacol. 2019 Jun 27. doi: 10.1002/jcph.1474. [Epub ahead of print]

PMID:
31243790
2.

A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor.

Dennie J, Vandell AG, Inoue S, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Uchiyama M, Yamada M, Senaldi G.

J Clin Pharmacol. 2018 Dec;58(12):1557-1565. doi: 10.1002/jcph.1151. Epub 2018 May 10.

PMID:
29746725
3.

Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.

Vandell AG, Inoue S, Dennie J, Nagasawa Y, Gajee R, Pav J, Zhang G, Zamora C, Masuda N, Senaldi G.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02537-17. doi: 10.1128/AAC.02537-17. Print 2018 May.

4.

A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.

Zhou J, Kochan J, Yin O, Warren V, Zamora C, Atiee G, Pav J, Orihashi Y, Vashi V, Dishy V.

J Thromb Haemost. 2017 May;15(5):961-971. doi: 10.1111/jth.13658. Epub 2017 Mar 11.

5.

HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction.

Pav JW, Rowland LS, Korpalski DJ.

J Pharm Biomed Anal. 1999 Jun;20(1-2):91-8.

PMID:
10704012
6.

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.

Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, Robinson P.

Biopharm Drug Dispos. 1999 Sep;20(6):285-91.

PMID:
10701699
7.

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, Keirns J.

Drug Metab Dispos. 1999 Aug;27(8):895-901.

PMID:
10421616
8.

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB.

AIDS. 1999 Mar 11;13(4):479-86.

PMID:
10197376
9.

[Personal experience with the treatment of organic hyperinsulinism].

Skrha J, Sindelka G, Krusina L, Hilgertová J, Páv J.

Vnitr Lek. 1998 Apr;44(4):217-21. Czech.

PMID:
9820106
10.

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.

Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL.

J Infect Dis. 1998 Aug;178(2):368-74.

PMID:
9697716
11.

Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.

Grob PM, Cao Y, Muchmore E, Ho DD, Norris S, Pav JW, Shih CK, Adams J.

Nat Med. 1997 Jun;3(6):665-70.

PMID:
9176494
12.

[Personal experience with the diagnosis of organic hyperinsulinism].

Skrha J, Sindelka G, Matĕjovská H, Hilgertová J, Justová V, Páv J.

Vnitr Lek. 1996 Sep;42(9):635-9. Czech.

PMID:
8984773
13.

[Factors with insulin-like effects: IGF-I and GLP-1].

Páv J.

Vnitr Lek. 1995 Sep;41(9):624-8. Review. Czech.

PMID:
7483355
14.

Clinical research of glucose metabolism.

Skrha J, Páv J.

Sb Lek. 1995;96(4):345-7.

PMID:
8711381
15.

[Thoughts on insulin therapy].

Páv J.

Cas Lek Cesk. 1994 Jun 27;133(13):394-6. Review. Czech.

PMID:
8062330
16.

[Hypoglycemia and modern treatment of diabetes].

Páv J.

Vnitr Lek. 1994 May;40(5):316-9. Czech.

PMID:
8023475
17.

Risk calculation of type 2 diabetes.

Haas T, Svacina S, Pav J, Hovorka R, Sucharda P, Sonka J.

Comput Methods Programs Biomed. 1994 Jan;41(3-4):297-303.

PMID:
8187472
18.

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.

Cheeseman SH, Hattox SE, McLaughlin MM, Koup RA, Andrews C, Bova CA, Pav JW, Roy T, Sullivan JL, Keirns JJ.

Antimicrob Agents Chemother. 1993 Feb;37(2):178-82.

20.

[Discussion of the article by J. Sobra: Nutrition and metabolic disorders of high incidence].

Páv J.

Cas Lek Cesk. 1991 Oct 18;130(16-17):525-6. Czech. No abstract available.

PMID:
1769050
21.

[Changes in the dietary regimen during treatment of type I diabetes mellitus with continuous insulin infusion. II. Omitting food].

Svacina S, Masek Z, Páv J, Kábrt J, Hilgertová J.

Cas Lek Cesk. 1991 Feb 15;130(7):202-5. Czech.

PMID:
2013073
22.

[Variations in the dietary regimen in type I diabetes mellitus. I. Short-term use of a high-carbohydrate diet].

Masek Z, Svacina S, Páv J, Kábrt J, Hilgertová J.

Cas Lek Cesk. 1991 Feb 15;130(7):199-201. Czech.

PMID:
2013072
23.

[The development of theories on the mechanisms of insulin action].

Páv J, Skrha J.

Cas Lek Cesk. 1990 Aug 24;129(34):1075-9. Czech.

PMID:
2224964
24.
25.

Glucose metabolism in a patient with insulinoma complicated by hyperosmolar non-ketotic state.

Skrha J, Páv J, Svacina S, Srámková J, Hilgertová J.

Diabet Med. 1990 May;7(4):361-3.

PMID:
2159861
26.

[A consulting system for insulin therapy in diabetes].

Hovorka R, Svacina S, Masek Z, Páv J.

Cas Lek Cesk. 1990 Apr 6;129(14):417-23. Czech.

PMID:
2188725
27.

[Hyperlipoproteinemia and the genetic epidemiology of diabetes mellitus].

Sobra J, Páv J, Ceska R.

Cas Lek Cesk. 1989 Dec 8;128(50):1575-9. Czech.

PMID:
2631992
28.

Food effects on the nighttime pharmacokinetics of Theo-Dur tablets.

Kann J, Levitt MJ, Horodniak JW, Pav JW.

Ann Allergy. 1989 Oct;63(4):282-6.

PMID:
2679244
29.

[The Biostator in the diagnosis and therapy of organic hyperinsulinism].

Skrha J, Päv J, Svacina S, Srámková J, Masek Z.

Cas Lek Cesk. 1989 Sep 8;128(37):1170-4. Czech.

PMID:
2680093
31.

Use of euglycaemic clamping in evaluation of diazoxide treatment of insulinoma.

Skrha J, Svacina S, Srámková J, Páv J.

Eur J Clin Pharmacol. 1989;36(2):199-201.

PMID:
2542036
32.

Insulin receptors and glucose homeostasis in type 2 diabetics influenced by acetyl-salicylic acid treatment.

Skrha J, Hilgertová J, Svacina S, Srámková J, Páv J.

Exp Clin Endocrinol. 1988 Sep;92(1):119-22.

PMID:
3229444
33.

[Problems surrounding substitution therapy with insulin].

Páv J, Skrha J.

Cas Lek Cesk. 1988 Jul 22;127(30):936-9. Czech. No abstract available.

PMID:
3048696
34.

[Glycoregulation in primary hyperparathyroidism].

Skrha J, Srámková J, Broulík P, Páv J.

Sb Lek. 1988 Jul;90(7):200-5. Czech. No abstract available.

PMID:
3065921
35.

[The effect of continuous subcutaneous administration of insulin on the oxidation of energy substrates in insulin-dependent diabetics].

Kábrt J, Páv J, Masek Z, Svacina S, Hovorka R.

Cas Lek Cesk. 1988 Apr 29;127(18):549-52. Czech. No abstract available.

PMID:
3396036
36.

[The effect of compensation in diabetes mellitus on energy metabolism in conventionally treated insulin-dependent diabetics].

Kábrt J, Páv J, Masek Z, Svacina S, Hovorka R.

Cas Lek Cesk. 1988 Apr 22;127(17):531-4. Czech. No abstract available.

PMID:
3293782
37.

[The insulin pump in type II diabetics].

Svacina S, Masek Z, Páv J, Kábrt J, Hovorka R, Ponka J.

Vnitr Lek. 1988 Feb;34(2):146-52. Czech. No abstract available.

PMID:
3284182
38.

[Personal experience with the stabilized blood glucose test (blood glucose clamp)].

Svacina S, Skrha J, Páv J, Hovorka R.

Vnitr Lek. 1988 Feb;34(2):138-45. Czech. No abstract available.

PMID:
3284181
39.

[Acylpyrin and glucose homeostasis in diabetes mellitus].

Skrha J, Svacina S, Hilgertová J, Srámková J, Hovorka R, Perusicová J, Masek Z, Páv J.

Cas Lek Cesk. 1988 Jan 29;127(5):144-8. Czech. No abstract available.

PMID:
3356032
40.

[Empirical risks in the development of diabetes. Genealogical studies in type 2 diabetics].

Páv J, Svacina S.

Cas Lek Cesk. 1988 Jan 22;127(4):108-12. Czech. No abstract available.

PMID:
3349510
41.
42.

[The diabetic in the inpatient internal medicine department].

Páv J, Svacina S, Nĕmcová V.

Vnitr Lek. 1987 Nov;33(11):976-81. Czech. No abstract available.

PMID:
3326255
43.

Comparison of N-acetyl-beta-glucosaminidase and albuminuria with clinical finding of microangiopathy in type I diabetes mellitus.

Skrha J, Perusicová J, Stolba P, Stibor V, Páv J.

Clin Chim Acta. 1987 Jul 15;166(2-3):135-41.

PMID:
3621594
44.

[The effect of acromegaly treatment on glucose tolerance].

Páv J, Marek J, Srámková J.

Cas Lek Cesk. 1986 Nov 21;125(47):1451-4. Czech. No abstract available.

PMID:
3791370
45.

[Macroangiopathy and microangiopathy in diabetes. IV. Vascular changes in type I diabetes--second examination after 4-5 years].

Sperl M, Páv J, Spácil J, Silinková-Málková E, Vancura J.

Vnitr Lek. 1986 Nov;32(11):1059-65. Czech. No abstract available.

PMID:
3798772
46.

[Macroangiopathy and microangiopathy in diabetes. III. Vascular changes in type I diabetics--initial examination].

Sperl M, Páv J, Spácil J, Silinková-Málková E, Vancura J.

Vnitr Lek. 1986 Nov;32(11):1051-8. Czech. No abstract available.

PMID:
3798771
47.
48.

[Macroangiopathy and microangiopathy in diabetes. II. Vascular changes in type 2 diabetics. Repeat examination after 4-5 years].

Páv J, Sperl M, Spácil J, Silinková-Málková E, Vancura J.

Vnitr Lek. 1986 Oct;32(10):986-90. Czech. No abstract available.

PMID:
3788076
49.

[Macroangiopathy and microangiopathy in diabetes. I. Vascular changes in type 2 diabetics. Initial examination].

Spácil J, Páv J, Sperl M, Silinková-Málková E, Vancura J.

Vnitr Lek. 1986 Sep;32(9):894-900. Czech. No abstract available.

PMID:
3765427
50.

[History of a world-wide priority originating in Prague].

Páv J.

Cas Lek Cesk. 1986 Jun 20;125(25):784-5. Czech. No abstract available.

PMID:
3521874

Supplemental Content

Support Center